You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Harvard Business School
Dow
AstraZeneca
Colorcon

Last Updated: September 18, 2020

DrugPatentWatch Database Preview

Patent: 7,015,328

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,015,328
Title:Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
Abstract: The present invention is directed to substituted coumarins and quinolines and analogs thereof, represented by the general Formula I: ##STR00001## wherein A, B, X, Y, and Z are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
Inventor(s): Cai; Sui Xiong (San Diego, CA), Zhang; Hong (San Diego, CA), Kemnitzer; William E. (San Diego, CA), Jiang; Songchun (San Diego, CA), Drewe; John (Carlsbad, CA), Storer; Richard (Pinner, GB)
Assignee: Cytovia, Inc. (San Diego, CA) Shire BioChem Inc. (Laval, CA)
Application Number:10/146,136
Patent Claims:see list of patent claims

Details for Patent 7,015,328

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Cytovia, Inc. (San Diego, CA) Shire BioChem Inc. (Laval, CA) 2021-05-16 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Cytovia, Inc. (San Diego, CA) Shire BioChem Inc. (Laval, CA) 2021-05-16 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Cytovia, Inc. (San Diego, CA) Shire BioChem Inc. (Laval, CA) 2021-05-16 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Merck
Moodys
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.